



HAL
open science

Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells

Marion Grard, Mohamed Idjellidaine, Atousa Arbabian, Camille Chatelain, Laurine Berland, Chantal Combredet, Soizic Dutoit, Sophie Deshayes, Virginie Dehame, Nathalie Labarrière, et al.

► To cite this version:

Marion Grard, Mohamed Idjellidaine, Atousa Arbabian, Camille Chatelain, Laurine Berland, et al.. Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells. *Cancer Immunology, Immunotherapy*, 2023, 72 (10), pp.3309-3322. 10.1007/s00262-023-03486-4 . inserm-04581137

HAL Id: inserm-04581137

<https://inserm.hal.science/inserm-04581137v1>

Submitted on 21 May 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II**
2 **presentation of this tumor antigen by melanoma and dendritic cells.**

3 Marion Grard^{1,2*}, Mohamed Idjellidaine^{1,2*}, Atousa Arbabian³, Camille Chatelain^{1,2}, Laurine
4 Berland^{1,2}, Chantal Combredet³, Soizic Dutoit^{1,2}, Sophie Deshayes^{1,2}, Virginie Dehame^{1,2},
5 Nathalie Labarrière^{2,4}, Delphine Fradin^{1,2}, Nicolas Boisgerault^{1,2}, Christophe Blanquart^{1,2},
6 Frédéric Tangy³ and Jean-François Fonteneau^{1,2}.

7

8 ¹ Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France

9 ² Labex IGO, Immunology Graft Oncology, Nantes, France

10 ³ CNRS 3569, Institut Pasteur, Paris, 75015, France.

11 ⁴ Nantes Université, Université d'Angers, Inserm, Immunology and New Concepts in
12 ImmunoTherapy, INCIT, UMR 1302, F-44000 Nantes, France

13

14 **Corresponding author:** Jean-François FONTENEAU, CRCIN2A, INSERM UMR1307,
15 CNRS UMR6075, Institut de Recherche en Santé de l'Université de Nantes, 8 quai Moncoussu,
16 BP 70721, 44007 Nantes cedex 1

17 Email: jean-francois.fonteneau@inserm.fr

18

19 **Short Title:** Measles virus encoding NY-ESO-1

20

21 * MG and MI equally contributed to this work.

22 **Abstract**

23 Antitumor virotherapy stimulates the antitumor immune response during tumor cell lysis
24 induced by oncolytic viruses (OV). OV can be modified to express additional transgenes that enhance
25 their therapeutic potential. In this study, we armed the spontaneously oncolytic Schwarz strain of
26 measles viruses (MV) with the gene encoding the cancer/testis antigen NY-ESO-1 to obtain MVny. We
27 compared MV and MVny oncolytic activity and ability to induce NY-ESO-1 expression in six human
28 melanoma cell lines. After MVny infection, we measured the capacity of melanoma cells to present NY-
29 ESO-1 peptides to CD4⁺ and CD8⁺ T cell clones specific for this antigen. We assessed the ability of
30 MVny to induce NY-ESO-1 expression and presentation in monocyte-derived dendritic cells (DC). Our
31 results show that MVny and MV oncolytic activity are similar with a faster cell lysis induced by MVny.
32 We also observed that melanoma cell lines and DC expressed the NY-ESO-1 protein after MVny
33 infection. In addition, MVny-infected melanoma cells and DC were able to stimulate NY-ESO-1
34 specific CD4⁺ and CD8⁺ T cells. Finally, MVny was able to induce DC maturation. Altogether, these
35 results show that MVny could be an interesting candidate to stimulate NY-ESO-1 specific T cells in
36 melanoma patients with NY-ESO-1-expressing tumor cells.

37

38 **Keywords**

39 antitumor immunotherapy, measles virus, melanoma, tumor antigen, NY-ESO-1, T cells.

40 **Introduction**

41 Antitumor virotherapy consists in using oncolytic viruses (OV) to treat cancer. OV are non-
42 pathogenic replicative viruses that infect, replicate in and kill tumor cells without harming healthy cells
43 [1]. Furthermore, infection of tumor cells by OV should result in immunogenic cell death that potentially
44 stimulate antitumor immune responses [2]. The combination of danger signals, tumor-associated
45 antigens (TAA) and pro-inflammatory cytokines released by infected and dying tumor cells activates
46 antigen-presenting cells such as dendritic cells (DC) that become able to initiate anti-tumor T cell
47 responses [3, 4].

48 Numerous TAA that are recognized by T cells via HLA molecules on the surface of tumor cells
49 have been identified [5]. They are classified as mutated, tumor-specific, differentiation or overexpressed
50 antigens. Tumor-specific TAA, also known as cancer/testis or cancer-germline antigens share interesting
51 properties for cancer immunotherapy with mutated neo-antigens. Their expression is restricted to tumor
52 cells and they are recognized by a specific T cell repertoire of high avidity [6]. In addition, their
53 expression is shared by a variety of tumors. New York esophageal squamous cell carcinoma 1 antigen
54 (NY-ESO-1) that is encoded by the gene *CTAG1B* is a tumor-specific TAA that is expressed in several
55 types of cancers such as melanoma or lung adenocarcinoma. This TAA is a good candidate for
56 immunotherapy since it can be spontaneously recognized in patients not only by cytotoxic CD8+ T
57 lymphocytes, but also by CD4+ T cells and B lymphocytes [7–9]. Several immunotherapy clinical trials
58 using NY-ESO-1 as a target are undergoing [10].

59 Measles virus (MV) is an enveloped, negative sense ssRNA paramyxovirus responsible for
60 Measles. The attenuated Schwarz strain of MV is commonly used for children vaccination. This strain
61 displays spontaneous oncolytic activity against numerous types of cancers, notably melanoma [11], lung
62 and colon adenocarcinoma [12] and malignant pleural mesothelioma [13, 14]. Other attenuated MV
63 strains such as the Edmonston strain are evaluated in clinical trials for the treatment of ovarian cancer,
64 glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck, breast cancers and
65 malignant peripheral nerve sheath tumors [15]. Despite a relatively small genome of around 16,000
66 nucleotides, MV can accept additional transgenes for use in antitumor virotherapy [16–18] or

67 prophylactic vaccination [19, 20]. Concept of TAA encoding OV for tumor vaccination was introduced
68 using Maraba virus encoding a melanoma antigen [21], and has been applied also to MV [22].

69 In this study, we generated MVny by insertion of the gene encoding NY-ESO-1 into the Schwarz
70 MV genome. We then evaluated MVny oncolytic activity against human melanoma cell lines and
71 observed that it was preserved compared to standard Schwarz MV. MVny induced a strong NY-ESO-1
72 expression in infected melanoma cell lines and a moderate expression in human monocyte-derived DC.
73 Finally, we demonstrated in vitro that melanoma cell lines or DC exposed to MVny present efficiently
74 NY-ESO-1 peptides to NY-ESO-1-specific CD8⁺ and CD4⁺ T cell clones. Altogether, our results
75 suggest that MVny might be an interesting OV to induce NY-ESO-1 presentation to T cells.

76

77 **Material and methods**

78 Tumor cells lines

79 The M18, M45, M88, M117 and M199 human melanoma cell lines were provided by Dr
80 Nathalie Labarrière (INCIT, Nantes) that are part of the PC-U892-NL Biocollection (CHU Nantes,
81 France). Samples were collected in accordance with the standards established by the Declaration of
82 Helsinki. All recruited patients gave signed informed consent. Study was approved by local ethical
83 committee (CPP Ouest-IV -Nantes). The IPC277/5 was provided by Dr C. Auben (INSERM, Marseille).
84 The cell lines were maintained at 37°C, under 100% humidity and 5% CO₂ in Roswell Park Memorial
85 Institute Medium (RPMI) 1640 (Gibco, France) supplemented with 100U/mL Penicillin (Gibco,
86 France), 100µg/mL Streptomycin (Gibco, France), 2mM L-Glutamine (Gibco, France), and 10% Fetal
87 Calf Serum (FCS, Eurobio) previously decomplexed. Cells were routinely checked for Mycoplasma
88 contamination using the Plasmotest from InvivoGen.

89

90 Human NY-ESO-1-specific T cell clones

91 NY67, a CD4+ T cell clone specific for the HLA-DPb*0401/NY-ESO-1(157-170) complex,
92 and N5.14, a CD8+ T cell clone specific for the HLA-A*0201/Mucin-1(950-958) complex were
93 obtained from blood donors as previously described [23, 24]. M.117.167, a CD8+ T cell clone specific
94 for the HLA A*0201/NY-ESO-1(157-165) complex was obtained from tumor-infiltrating lymphocytes
95 (TILs) from a melanoma patient biopsy [25]. The clones were seeded for amplification at 5,000
96 cells/well in 150µL of RPMI 1640 (Gibco) supplemented with 100U/mL Penicillin (Gibco), 100µg/mL
97 Streptomycin (Gibco), 2mM L-Glutamine (Gibco), 8% pooled human serum and containing 1µg/mL of
98 Leucoagglutinin PHA-L (Sigma, cat #L2769450), 150 UI/mL IL-2 (Proleukin, CHIRON) and irradiated
99 feeder cells in 96-well round bottom plates. The feeder cells consisted of a B lymphocyte cell line
100 immortalized by the Epstein Barr virus and peripheral blood mononuclear cells (PBMC) irradiated at 70
101 and 35 Gy and seeded at 1.10⁴ and 1.10⁵ cells per well, respectively. NY-ESO-1(157-165),
102 SLLMWITQC, and NY-ESO-1(157-170), SLLMWITQCFLPVF, peptides were purchased from
103 Eurogentech.

104

105 Human monocyte-derived DC

106 Blood monocytes were obtained by negative magnetic sorting (EasySep Human monocyte
107 Enrichment Kit, StemCell) from PBMC of healthy donors provided by EFS (Etablissement Français du
108 Sang, Nantes) as previously described [26]. Immature DCs were differentiated for 5 days from
109 monocytes, seeded at $2 \cdot 10^6$ cells/mL in a 6-well plate with culture medium composed of RPMI 1640
110 (Gibco, France) supplemented with 100U/mL Penicillin (Gibco), 100 μ g/mL Streptomycin (Gibco,
111 France), 2mM L-Glutamine (Gibco), 2% human albumin (Human Albumin 200 mg/mL, VIALEBEX),
112 1000IU/mL of GM-CSF (CellGenix) and 200IU/mL of Interleukin-4 (CellGenix). After 5 days
113 immature DCs were collected for experiments.

114

115 Attenuated Schwarz MV, MVeGFP and MVny

116 Live-attenuated Schwarz-strain measles virus vaccine (MV), MV recombinant for the enhanced
117 green fluorescent protein (MVeGFP), and MV recombinant for NY-ESO-1 (MVny) were produced and
118 purified as previously described [27]. To generate MVny recombinant virus, the cDNA sequence of
119 human NY-ESO-1 ORF (*CTAG1B*, clone NM 001327) was codon optimized for MV expression,
120 modified at the stop codon to ensure that the total number of nucleotides is a multiple of six [19], and
121 subsequently cloned into an additional transcription unit localized between the P and M genes in the
122 pTM-MV Schw plasmid encoding infectious MV Schw cDNA corresponding to the antigenome of the
123 MV Schwarz vaccine strain [27]. Rescue of recombinant virus was performed as previously described
124 using a helper-cell-based system [27]. Briefly, helper HEK293T cells expressing both the T7-RNA
125 polymerase and the Schwarz MV N and P proteins (HEK293-T7-MV) were co-transfected with pTM-
126 MV Schw-NY-ESO-1 vector plasmid and a plasmid expressing the Schwarz MV polymerase L.
127 Transfected HEK293-T7-MV helper cells were gently harvested and co-cultured with Vero cells for
128 amplification of MV Schw-NY-ESO-1 virus. Virus titers were determined by endpoint titration on Vero
129 cells and expressed as TCID₅₀/ml. Replication of MV Schw-NY-ESO-1 recombinant virus was
130 analyzed by single-step growth curves on Vero cells using an MOI of 0.1. The growth rate of
131 recombinant MV Schw-NY-ESO-1 virus was similar to empty MV Schw.

132

133 Western blot assay

134 Vero Cells, Tumor cell lines or monocyte-derived DC were seeded at $5 \cdot 10^5$ cells/mL and
135 infected with MV or MVny at a multiplicity of infection (MOI) of 1 in a 24-well plate in their respective
136 media. After 48 hours of infection, cells were lysed in $100 \mu\text{L}/1 \cdot 10^6$ cells of RIPA lysis buffer (Radio
137 immunoprecipitation assay buffer, Sigma-Aldrich) with 1% protease inhibitor (Sigma-Aldrich). Twenty
138 μg of proteins were denatured at 95°C for 5 minutes in Laemmli buffer (BioRad) with 10% beta-
139 mercaptoethanol (Merck) before plating into a pre-cast SDS-polyacrylamide 4-15% electrophoresis gel
140 (BioRad). Migration was performed at 200V for 30min in 10x Tris/Glycine/SDS migration buffer
141 (BioRad, cat #1610772). After migration, proteins were transferred to a Polyvinylidene difluoride
142 (PVDF) membrane, which was then blocked with 0.1% Tween tris-buffered saline (T-TBS) containing
143 5% milk. The membrane was incubated with a rabbit anti-NY-ESO-1 primary antibody (Cell Signaling
144 Technology, Cat #45437) at 4°C overnight at 1:1000 or with a rabbit anti-Actin primary antibody (Cell
145 Signaling Technology, cat # 3700) for one hour at room temperature at 1:1000. After 3 washes with
146 0.1% T-TBS, the membrane was incubated with horseradish peroxidase (HRP)-coupled anti-rabbit
147 secondary antibody (Jackson Immuno Research) for one hour at 1:5000. Proteins were revealed with the
148 Clarity TM Western ECL chemiluminescence kit (BioRad) by the Chemi DOC TM Imaging system
149 (BioRad). The analysis of the images was performed with the ImageLab software.

150

151 Propidium iodide / annexin V Staining

152 CD8+ T cell clone N5.14, tumor cell lines or immature monocyte-derived DCs were seeded at
153 $5 \cdot 10^5$ cells/mL and infected with MV or MVny (MOI=1) in a 48-well plate in their respective media.
154 After 48h, 72h, 96h or 120h of infection, the cells were labeled with propidium iodide (PI) / FITC
155 Annexin V Apoptosis Detection Kit I (BD Pharmingen Cat #556547) and analyzed by flow cytometry.

156

157 Intracytoplasmic staining of IFN- γ

158 HLA-A*0201+ or HLA-DPb1*0401+ immature DCs and tumor cells were seeded in a 96-well
159 flat-bottom plate at $1.2 \cdot 10^6$ cells/mL in $100 \mu\text{L}$ of their culture medium and were infected or not with
160 MV or MVny (MOI=1). After 48 hours, some uninfected DC and tumor cells were incubated 1 hour at

161 room temperature with 10 μ M of NY-ESO-1 (157-165) or (157-170) peptides and then washed.
162 Uninfected, peptide-pulsed and unwashed infected DCs or tumor cells were co-cultured with the CD4+
163 T cell clone NY67 or with the CD8+ T cell clone M.117.167 in presence of 10 μ g/mL of brefeldin A
164 (BioLegend, cat #420601). After 5 h of co-culture, cells were fixed with PBS 4% paraformaldehyde
165 (PFA) (Electron Microscopy Sciences) for 10 minutes and labeled with a FITC-conjugated anti-CD4
166 (BD Pharmingen) or a FITC-conjugated anti-CD8 (BioLegend), and a PE-conjugated anti-IFN- γ (BD
167 /Pharmingen, Cat # 554701) mAb, diluted in PBS with 0.1% bovine serum albumin (BSA) and 0.1%
168 saponin, for 30 minutes. Cells were then analyzed by flow cytometry with a BD FACS *Canto II*
169 cytometer. The software *Diva* was used for the analysis.

170

171 *MVgfp replication in monocyte-derived DC, M88 melanoma cell line and N5.14 CD8+ T cell clone*

172 N5.14 CD8+ T cell clone, M88 melanoma cell line and monocyte-derived DCs were seeded in
173 a 48-well plate at 5.10⁵ in 800 μ L of their respective culture media. They were exposed to MVeGFP
174 (MOI=1). The fluorescence was recorded by time-lapse microscopy using a *Widefield Leica DMI8*,
175 *driven by Metamorph v7.8 software* (Molecular Devices), with environmental control (Temperature,
176 humidity and CO₂) for 120h using a x10 objective. Fluorescence was calculated from two different fields
177 per wells with the *ImageJ* software [28].

178

179 *RT-qPCR*

180 The M88 melanoma cell line and iDCs were seeded in a 48-well plate at 5.10⁵ cells/mL and
181 2.10⁶ cells/mL, respectively, in 500 μ L of their respective culture media. They were exposed to MV or
182 MVny (MOI=1). After 48h, cellular RNAs were extracted using the Nucleospin® RNA plus kit
183 (Macherey-Nagel, Cat #740984.10) and 250ng were reverse-transcribed (Invitrogen, Cat #28025013).
184 The qPCR reaction is then performed using Master mix Maxima SYBR Green/ROX qPCR (Thermo
185 Scientific, Cat #K0253). The expression of NY-ESO-1 was measured using a pair of QuantiTect primers
186 for NY-ESO-1. NY-ESO-1 gene expression was normalized against the expression of the housekeeping
187 gene encoding the Ribosomal Protein Lateral Stalk Subunit P0 (RPLP0). Each reaction sample was run
188 in duplicate. To circumvent any issue of non-specific amplification melting curve analysis was

189 performed with a temperature gradient of 70-95°C. The $2^{-\Delta\Delta Ct}$ method was used to calculate relative
190 changes in expression [29].

191

192 Surface staining of human monocyte-derived DCs

193 Monocyte-derived DCs were seeded in a 48-well plate at 5.10^5 cells/mL in 1mL of their culture
194 medium. They were infected with MV or MVny (MOI=1), or treated with 1µg/mL lipopolysaccharide
195 (LPS) (Sigma-Aldrich Cat #L2654-1 MG). After 48h of incubation, they were labeled 30 minutes with
196 anti CD80 APC-H7-conjugated (IgG1k, BD Cat#561134), an anti-CD83 FITC-conjugated (IgG1k,
197 Biosciences Cat #556910), an anti-CD86 APC-conjugated (IgG1k, BD Biosciences Cat#555660), an
198 anti-HLA-ABC FITC-conjugated (IgG2a, Beckman Coulter, Cat#IM1838U), an anti-HLA-DP
199 BUV395-conjugated (IgG1k, BD, 750866) or respective fluorescent isotype control mAb diluted in PBS
200 with 0.1% BSA in presence of Fc block (BD Pharmingen, Cat#564220). Cells were washed and then
201 fixed in PBS with 1% PFA for flow cytometric analysis with a BD FACS *Canto II* cytometer and the
202 Diva software.

203

204 Data formatting and statistical analysis

205 The data were formatted using *GraphPad Prism* v8. Statistical significance were determined by
206 the Mann-Witney Wilcoxon signed ranks test and Kruskal Wallis test (* $p < 0.05$; ** $p < 0.01$)

207 **Results**

208 *MVny induces NY-ESO-1 expression in human melanoma cells and cell lysis*

209 MVny was generated by inserting the gene encoding the tumor associated antigen NY-ESO-1
210 in the genome of the Schwarz MV between the genes encoding P/V/C and M proteins (Figure 1A). The
211 recombinant MVny virus was obtained by reverse genetics using a helper-cell-based system and
212 amplified on Vero cells. The modified virus replicated similarly to the parental Schwarz strain of MV
213 and expressed high levels of NY-ESO-1 protein in infected Vero cells (Figures 1B).

214 We previously described that a majority of human melanoma cell lines are permissive *in vitro*
215 to MV replication due to defects in their antiviral type I interferon pathway [11]. In this experiment, we
216 evaluated by western blot if the tumor antigen NY-ESO-1 is expressed after *in vitro* exposure of five
217 melanoma cell lines to MVny, using the human M18 melanoma cell line that expresses NY-ESO-1 as a
218 control. First, we observed that among the melanoma cell lines studied, two cell lines, M18 and
219 IPC277/5, expressed NY-ESO-1 (Figure 2A). After 48h of exposition to MVny, the five melanoma cell
220 lines expressed high levels of NY-ESO-1 (Figure 2B). NY-ESO-1 expression induced by MVny was
221 higher than its spontaneous expression in M18 and IPC277/5.

222 We then assessed by propidium iodide and annexinV staining if exposition of the 6 melanoma
223 cell lines to MV or MVny led to cell lysis. After 48h, it was often too early to detect lysis induced by
224 MV (Figures 3A and 3B). However, we detected about 15% more cell death when IPC277/5 cells were
225 infected with both viruses. We observed around 40% and 30% additional cell death in M18 and M88
226 induced by MVny compared to MV, respectively. After 120h, the same level of cell death was induced
227 by MV and MVny in all cell lines, except for M199 that was better lysed by MV (Figure 3C and 3D).
228 We also observed that M45 was quite resistant to the oncolytic activity of both viruses showing only
229 around 10% lysis. Altogether, these results show that MVny has an equivalent oncolytic activity
230 compared to MV that is faster for a few melanoma cell lines such as M18 and M88.

231

232 *MVny induces recognition of melanoma cell lines by NY-ESO-1-specific CD4+ and CD8+ T cell clones*

233 To determine whether HLA-A*0201+ melanoma cell line M199 is able to present the NY-ESO-
234 1(157-165) peptide after infection by MVny, we measured IFN- γ production by M117.167, a human

235 CD8+ T cell clones specific for the complex HLA-A*0201/NY-ESO-1(157-165) (Figure 4A-C). The
236 M117.167 clone was unable to recognize M199 alone or exposed to MV, whereas it was able to produce
237 IFN- γ in response to M199 pulsed with NY-ESO-1(157-165) peptide or after infection with MVny. This
238 production of IFN- γ by M117.167 in response to MVny infected M199 cell lines was modest after 48h
239 (Figures 4A and 4C), but reached a high level comparable to the production observed in response to
240 10 μ M of peptide after 120h (Figures 4B and 4C). In the same experiments, we also assessed M117.167
241 response to the autologous HLA-A*0201+ tumor cell lines M117. This cell line and the M117.167 T
242 cell clone were obtained from the same melanoma biopsy. Non-infected M117 was recognized by
243 M117.167 and this recognition was comparable after peptide loading or infection by MV or MVny
244 (Figure S1A and S1B). We failed to detect NY-ESO-1 protein by western blot in the non-infected M117
245 cell line (Figure 2), but we found NY-ESO-1 mRNA by RT-PCR in this cell lines (Figure S1C). We
246 performed an additional experiment that show that MVny does not induces the recognition of M199 by
247 a MUC1(950-956) specific CD8+ T cell clones and that the NY-ESO-1 specific T cell clone M117.167
248 does not recognize MV encoding cherry protein (MVch) infected M199 cells (Figure S2).

249 We also used NY67, a human CD4+ T cell clone specific for the HLA-DPB1*0401/NY-ESO-
250 1(157-170) complex, to determine if the HLA-DPB1*0401+ melanoma cell line M88 was able to present
251 the NY-ESO-1(157-170) peptide after infection by MVny (Figure 4D to 4F). The NY67 clone was
252 unable to recognize M88 alone or exposed to MV, whereas IFN- γ was produced in response to M88
253 pulsed with NY-ESO-1(157-170) peptide or after infection with MVny. This production of IFN- γ by
254 NY67 in response to the MVny-infected M88 cell line was comparable to the production observed in
255 response to 10 μ M of peptide after 48h of infection (Figure 4D and 4E) and then decreased after 120h
256 (Figure 4D and 4F).

257 Finally, we measured HLA-DP and HLA-A*0201 expression by M88 and M199 melanoma cell
258 lines exposed to MV or MVny. After 48h, we observed no effects of both viruses on HLA-DP expression
259 and slight decrease of HLA-A*0201 expression induced by MVny (Figure S3).

260 Altogether, these experiments show that the expression of NY-ESO-1 by melanoma cell lines
261 after infection by MVny allows the cells to present efficiently the tumor antigen to CD4+ and CD8+ T
262 cells via HLA class II and I molecules, respectively.

263

264 *MVny induces NY-ESO-1 expression in human monocyte-derived DC and cell lysis*

265 We first analyzed MV replication in monocyte-derived DC using MV encoding the enhanced
266 green fluorescent protein (MVeGFP). Fluorescence was detected as soon as 20h after virus exposition
267 in DC and M88 melanoma cells (Figure 5A). While in M88 cell line fluorescence reached a mean plateau
268 around 250 FU after 96h of culture, in DC fluorescence peaked at a mean level of 8 FU after 30 hours
269 and then slowly decreased. At fluorescence peak, DC that were permissive to MV replication appeared
270 slightly green in the middle of non-fluorescent DC aggregates (Figure 5B). We failed to detect any
271 fluorescence after exposition of the human CD8+ T cell clone N5.14 to MVegfp (Figure 5A). These
272 results show that MV replicates moderately in monocyte-derived DC, confirming our previous
273 observation [3].

274 We then measured by RT-PCR and western blot the NY-ESO-1 expression in monocyte-derived
275 DC exposed for 48h to MV or MVny. As expected, NY-ESO-1 was not expressed by uninfected DC or
276 DC infected with MV, whereas expression was detected in DC exposed to MVny (Figure 5C). However,
277 the amount of NY-ESO-1 protein in MVny-infected DC was lower than in MVny-infected M88 cell line
278 (Figure 5D).

279 We evaluated monocyte-derived DC cell death after exposition to MV or MVny using
280 propidium iodide / annexin V staining (Figure 6). We observed that MVny induced cell death faster than
281 MV in both monocyte-derived DC and M88 melanoma cells. We did not observe cell death of N5.14
282 CD8+ T cells when exposed to MV or MVny.

283 We then assessed if MVny was able to induce DC maturation. DC maturation was observed 48h
284 after infection by MV or MVny when more than a half of DC are still alive, using LPS exposed DC as
285 a positive control. MVny induced DC maturation that is significant only for HLA-DR expression and
286 this maturation was less intense than LPS (Figure 7).

287 Altogether these results show that MVny is able to induce maturation of monocyte-derived DC
288 and expression of small amounts of NY-ESO-1 proteins, but also to induce significant DC cell death.

289

290 *MVny induces recognition of DC by NY-ESO-1-specific CD4+ and CD8+ T cell clones*

291 We finally determined if monocyte-derived DC exposed to MVny were able to present the NY-
292 ESO-1 antigen to specific CD4+ and CD8+ T cells. The NY-ESO-1 specific CD8+ T cell clone
293 M117.167 strongly responded by IFN- γ production when exposed to MVny-infected HLA-A*0201+
294 DC or pulsed with 10 μ M specific peptide, while it produce low level of IFN- γ in response to non-
295 infected or MV-infected DC (Figure 8). Similarly, the NY-ESO-1 specific CD4+ T cell clone NY67
296 produced high amounts of IFN- γ in response to DC exposed to MVny-infected DC or pulsed with 10 μ M
297 of peptide, while it produced low levels in response to non-infected or MV-infected HLA-DPB1*0401+
298 monocyte-derived DC (Figure 8). In this experiment, we also observed a low amount of IFN- γ that is
299 produced by both clones in response to MV-infected DC. This low IFN- γ amount is due to type I IFN
300 produced by DC in response to MV, since it can be inhibited by ruxolitinib that is an inhibitor of JAK1/2
301 and consequently of the IFN- α / β receptor signaling (Figure S4). In the meantime, the recognition of
302 MVny-infected DC by the clones is not altered by ruxolitinib. Thus, MVny-infected DC are able to
303 express the NY-ESO-1 and to present efficiently peptides from this tumor antigen to CD4+ and CD8+
304 T lymphocytes through HLA molecules.

305 Discussion

306 In a previous study, we showed that a majority of melanoma cell lines are sensitive to the
307 oncolytic activity of the Schwarz strain of MV due to defects of the antiviral type I interferon pathway
308 in tumor cells [11]. In this study, we show that the attenuated Schwarz MV encoding human NY-ESO-
309 1 is able to express this tumor antigen in infected melanoma tumor cells, while retaining its oncolytic
310 activity. Upon infection of melanoma cells, NY-ESO-1 is strongly expressed and NY-ESO-1 peptides
311 (157-165 and 157-170) are efficiently presented by infected tumor cells to specific CD8+ and CD4+ T
312 cells by HLA class I and II molecules. We also show that MVny replicates modestly in monocyte-
313 derived DCs compared to melanoma cells, allowing DCs to present NY-ESO-1 peptides to specific
314 CD4+ and CD8+ T cells. Altogether, these results demonstrate that MVny displays an oncolytic activity
315 against melanoma cell lines and induces NY-ESO-1 peptides presentation not only by tumor cells, but
316 also by antigen presenting cells such as monocyte-derived DCs.

317 Recently, Elena Busch and collaborators showed that MV can be modified to encode TAAs
318 [22]. They demonstrated using mouse cells that TAAs are expressed by tumor and dendritic cells after
319 TAA-encoding MV infection and that they are presented to CD8+ T cells. In this study, we confirm
320 their finding using human cells. We further show that MV encoding TAA can induce HLA class II
321 presentation by tumor cells and DCs to CD4+ T cells.

322 We observed that MVny induced a faster cell death than MV in some melanoma cell lines and
323 in DCs. Attenuated MV replication in human DCs has already been reported, albeit at a lower level than
324 wild type MV [3, 30]. This weak replication in DC is believed to be part of its great effectiveness as a
325 vaccine. The expression of NY-ESO-1 seems toxic for cells. It is difficult to formulate hypothesis
326 regarding this increased toxicity of MVny since the role of NY-ESO-1 is not well defined [10]. It is also
327 possible that this faster cell death may be due to the production of more non-encapsidated 5' copy-back
328 defective interfering Genomes (DI-RNA) during MV replication due to the presence of a transgene [31,
329 32]. DI-RNA are strong activator of the IFN I response via RIG-I that may lead to cell death induction.
330 We and other previously showed that MV induces immunogenic cell death allowing the release of
331 danger signals that mature DC [3, 33].

332 We previously showed that melanoma cell lines expressing NY-ESO-1 and HLA class II
333 molecules can present NY-ESO-1 peptides to NY-ESO-1-specific CD4+ T cells by an exogenous
334 pathway [34]. Indeed, some NY-ESO-1 proteins are released by melanoma cells and re-captured to reach
335 the endo-lysosomal HLA class II presentation pathway. We also reported that MV-induced cell death
336 allows the release of high amounts of NY-ESO-1 proteins leading to an increase HLA class II
337 presentation of this antigen by living tumor cells around [35]. Thus, MVny would reinforce NY-ESO-1
338 expression in tumors and its release by tumor cells leading to a strong presentation to CD4+ T cells.
339 Furthermore, NY-ESO-1 expression in melanoma tumors is often heterogeneous, exhibiting a mosaic-
340 like pattern with only isolated parts of the tumor expressing this antigen [36]. MVny may be an
341 interesting tools to spread NY-ESO-1 antigen presentation to regions of the tumor that do not express
342 NY-ESO-1.

343 The frequency of patients with NY-ESO-1-expressing melanoma correlates with the stage of
344 the disease. This expression is low in first stages and reaches around 45% in metastatic melanoma [36–
345 38]. MVny may be interesting to induce or reinforce NY-ESO-1 specific T cell responses for patient
346 with tumors that express this tumor antigen. Several immunotherapy clinical trials are on-going to
347 induce CD4+ and CD8+ T cell response against NY-ESO-1 [10]. For exemple, the adoptive transfer of
348 an autologous HLA-DPB*0401/NY-ESO-1(157-170)-specific CD4+ T lymphocyte clone in a
349 metastatic melanoma patient allowed the rejection of tumors and the emergence of other TAA-specific
350 T cells, thereby suggesting the induction of antigen spreading [39]. In addition, the adoptive transfer of
351 CD8+ T cells harboring a transgenic T cell receptor against NY-ESO-1 resulted in clinical benefits in
352 HLA-A*0201+ melanoma patients [40]. Thus, strategies aiming at increasing the presentation of this
353 TAA by DC and tumor cells not only through the HLA class I pathway, but also through the class II
354 pathway, should be envisaged to stimulate NY-ESO-1 antitumor immune responses. The use of
355 oncolytic viruses expressing NY-ESO-1, such as MVny, may be a valuable therapeutic strategy to
356 achieve this goal.

357 **Acknowledgments**

358 We thank Philippe Hulin and the cellular and tissular core facility of Nantes University (MicroPiCell)
359 for their expertise in video microscopy. We thank Nicolas Jouand and the core facility of flow cytometry
360 from Nantes University (Cytocell).

361

362 **Founding**

363 This work was supported by “La Ligue Régionale Grand Ouest contre le Cancer” (CD16, CD22, CD44,
364 CD49, CD72, CD79 and CD85), “l’association ARSMESO44 ”, “la Fondation ARC (PJA
365 20191209661)”, “l’Agence Nationale pour la Recherche (ANR-16-CE18-0016)”, and “LabEX IGO”
366 program supported by the National Research Agency via the investment of the future program ANR-
367 11-LABX-0016-01”.

368

369 **Disclosure statement**

370 FT and JFF are authors of patents on MV. FT owns equity in Oncovita, an oncolytic virotherapy
371 company.

372

373 **Author contributions**

374 Experiments conception: FT and JFF

375 Experiments: MG, MI, AA, CCh, LB, CCo, SD, VD, NB and JFF

376 Data analysis and manuscript writing: MG, NL, DF, NB, CB, FT and JFF.

377

378 **Data availability statement**

379 The data that support the findings of this study are available from the corresponding author (jean-
380 francois.fonteneau@inserm.fr) upon reasonable request.

381

382 **References**

- 383 1. Macedo N, Miller DM, Haq R, Kaufman HL (2020) Clinical landscape of oncolytic virus
384 research in 2020. *J Immunother Cancer* 8
- 385 2. Achard C, Surendran A, Wedge ME, et al (2018) Lighting a Fire in the Tumor
386 Microenvironment Using Oncolytic Immunotherapy. *EBioMedicine* 31:17–24
- 387 3. Gauvrit A, Brandler S, Sapede-Peroz C, et al (2008) Measles virus induces oncolysis of
388 mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
389 *Cancer Res* 68:4882–92
- 390 4. Guillaume JB, Boisgerault N, Roulois D, et al (2013) Measles virus vaccine-infected tumor cells
391 induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. *Clin Cancer Res*
392 19:1147–58
- 393 5. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized
394 by T lymphocytes: at the core of cancer immunotherapy. *Nat Rev Cancer* 14:135–46
- 395 6. Meng X, Sun X, Liu Z, He Y (2021) A novel era of cancer/testis antigen in cancer
396 immunotherapy. *Int Immunopharmacol* 98:107889
- 397 7. Gnjjatic S, Nishikawa H, Jungbluth AA, et al (2006) NY-ESO-1: review of an immunogenic
398 tumor antigen. *Adv Cancer Res* 95:1–30
- 399 8. Jager E, Chen YT, Drijfhout JW, et al (1998) Simultaneous humoral and cellular immune
400 response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility
401 leukocyte antigen (HLA)-A2-binding peptide epitopes. *J Exp Med* 187:265–70
- 402 9. Wang RF, Wang HY (2017) Immune targets and neoantigens for cancer immunotherapy and
403 precision medicine. *Cell Res* 27:11–37
- 404 10. Thomas R, Al-Khadairi G, Roelands J, et al (2018) NY-ESO-1 Based Immunotherapy of Cancer:
405 Current Perspectives. *Front Immunol* 9:947
- 406 11. Allagui F, Achard C, Panterne C, et al (2017) Modulation of the Type I Interferon Response
407 Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus. *Current gene*
408 *therapy* 16:419—428. <https://doi.org/10.2174/1566523217666170102110502>
- 409 12. Boisgerault N, Guillaume JB, Pouliquen D, et al (2013) Natural oncolytic activity of live-
410 attenuated measles virus against human lung and colorectal adenocarcinomas. *Biomed Res Int*
411 2013:387362
- 412 13. Achard C, Boisgerault N, Delaunay T, et al (2015) Sensitivity of human pleural mesothelioma to
413 oncolytic measles virus depends on defects of the type I interferon response. *Oncotarget*
414 6:44892—44904. <https://doi.org/10.18632/oncotarget.6285>
- 415 14. Delaunay T, Achard C, Boisgerault N, et al (2020) Frequent Homozygous Deletions of Type I
416 Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
417 *Journal of thoracic oncology : official publication of the International Association for the Study*
418 *of Lung Cancer* 15:827—842. <https://doi.org/10.1016/j.jtho.2019.12.128>
- 419 15. Msaouel P, Opyrchal M, Dispenzieri A, et al (2018) Clinical Trials with Oncolytic Measles
420 Virus: Current Status and Future Prospects. *Curr Cancer Drug Targets* 18:177–187

- 421 16. Backhaus PS, Veinalde R, Hartmann L, et al (2019) Immunological Effects and Viral Gene
422 Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15
423 Agonists. *Viruses* 11
- 424 17. Speck T, Heidbuechel JPW, Veinalde R, et al (2018) Targeted BiTE Expression by an Oncolytic
425 Vector Augments Therapeutic Efficacy Against Solid Tumors. *Clin Cancer Res* 24:2128–2137
- 426 18. Dispenzieri A, Tong C, LaPlant B, et al (2017) Phase I trial of systemic administration of
427 Edmonston strain of measles virus genetically engineered to express the sodium iodide
428 symporter in patients with recurrent or refractory multiple myeloma. *Leukemia* 31:2791–2798
- 429 19. Frantz PN, Barinov A, Ruffie C, et al (2021) A live measles-vectored COVID-19 vaccine
430 induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. *Nat*
431 *Commun* 12:6277
- 432 20. Ramsauer K, Schwameis M, Firbas C, et al (2015) Immunogenicity, safety, and tolerability of a
433 recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-
434 controlled, active-comparator, first-in-man trial. *Lancet Infect Dis* 15:519–27
- 435 21. Pol JG, Zhang L, Bridle BW, et al (2014) Maraba Virus as a Potent Oncolytic Vaccine Vector.
436 *Molecular Therapy* 22:420–429. <https://doi.org/10.1038/mt.2013.249>
- 437 22. Busch E, Kubon KD, Mayer JKM, et al (2020) Measles Vaccines Designed for Enhanced CD8+
438 T Cell Activation. *Viruses* 12:242. <https://doi.org/10.3390/v12020242>
- 439 23. Fonteneau JF, Larsson M, Somersan S, et al (2001) Generation of high quantities of viral and
440 tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic
441 cells. *J Immunol Methods* 258:111–26
- 442 24. Roulois D, Vignard V, Gueugnon F, et al (2011) Recognition of pleural mesothelioma by mucin-
443 1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells. *Eur Respir J* 38:1117–26
- 444 25. Benlalam H, Labarrière N, Linard B, et al (2001) Comprehensive analysis of the frequency of
445 recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes
446 (TIL): implications for immunotherapy. *Eur J Immunol* 31:2007–2015.
447 [https://doi.org/10.1002/1521-4141\(200107\)31:7<2007::aid-immu2007>3.0.co;2-s](https://doi.org/10.1002/1521-4141(200107)31:7<2007::aid-immu2007>3.0.co;2-s)
- 448 26. Coulais D, Panterne C, Fonteneau JF, Gregoire M (2012) Purification of circulating
449 plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic
450 beads. *Cytotherapy* 14:887–96
- 451 27. Combredet C, Labrousse V, Mollet L, et al (2003) A molecularly cloned Schwarz strain of
452 measles virus vaccine induces strong immune responses in macaques and transgenic mice. *J*
453 *Virology* 77:11546–54
- 454 28. Schindelin J, Arganda-Carreras I, Frise E, et al (2012) Fiji: an open-source platform for
455 biological-image analysis. *Nat Methods* 9:676–82
- 456 29. Bustin SA, Benes V, Garson JA, et al (2009) The MIQE Guidelines: Minimum Information for
457 Publication of Quantitative Real-Time PCR Experiments. *Clinical Chemistry* 55:611–622.
458 <https://doi.org/10.1373/clinchem.2008.112797>
- 459 30. Ohgimoto K, Ohgimoto S, Ihara T, et al (2007) Difference in production of infectious wild-type
460 measles and vaccine viruses in monocyte-derived dendritic cells. *Virus Research* 123:1–8.
461 <https://doi.org/10.1016/j.virusres.2006.07.006>

- 462 31. Sanchez David RY, Combredet C, Sismeiro O, et al (2016) Comparative analysis of viral RNA
463 signatures on different RIG-I-like receptors. *eLife* 5:e11275. <https://doi.org/10.7554/eLife.11275>
- 464 32. Mura M, Combredet C, Najburg V, et al (2017) Nonencapsidated 5' Copy-Back Defective
465 Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by RIG-I and
466 LGP2 but Not MDA5. *Journal of Virology* 91:e00643-17. <https://doi.org/10.1128/JVI.00643-17>
- 467 33. Donnelly OG, Errington-Mais F, Steele L, et al (2011) Measles virus causes immunogenic cell
468 death in human melanoma. *Gene Ther*
- 469 34. Fonteneau JF, Brilot F, Munz C, Gannage M (2016) The Tumor Antigen NY-ESO-1 Mediates
470 Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer. *J*
471 *Immunol* 196:64–71
- 472 35. Delaunay T, Violland M, Boisgerault N, et al (2018) Oncolytic viruses sensitize human tumor
473 cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. *Oncoimmunology*
474 7:e1407897. <https://doi.org/10.1080/2162402x.2017.1407897>
- 475 36. Velazquez EF, Jungbluth AA, Yancovitz M, et al (2007) Expression of the cancer/testis antigen
476 NY-ESO-1 in primary and metastatic malignant melanoma (MM)—correlation with prognostic
477 factors. *Cancer Immun* 7:11
- 478 37. Barrow C, Browning J, MacGregor D, et al (2006) Tumor antigen expression in melanoma
479 varies according to antigen and stage. *Clin Cancer Res* 12:764–71
- 480 38. Goydos JS, Patel M, Shih W (2001) NY-ESO-1 and CTp11 expression may correlate with stage
481 of progression in melanoma. *J Surg Res* 98:76–80
- 482 39. Hunder NN, Wallen H, Cao J, et al (2008) Treatment of metastatic melanoma with autologous
483 CD4+ T cells against NY-ESO-1. *N Engl J Med* 358:2698–703
- 484 40. Robbins PF, Kassim SH, Tran TL, et al (2015) A pilot trial using lymphocytes genetically
485 engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with
486 response. *Clin Cancer Res* 21:1019–27
- 487

488 **Figure legends**

489 Figure 1: Generation of MVny. (A) Schematic representation of pTM-MVny plasmid vector with the
490 NY-ESO-1 ORF sequence inserted into an additional transcription unit between the PVC and M genes.
491 The MV genome comprises the nucleoprotein (N), phosphoprotein (P), V and C accessory proteins,
492 matrix (M), fusion (F), hemagglutinin (H) and polymerase (L) genes. Plasmid elements include the T7
493 RNA polymerase promoter (T7), hammerhead ribozyme (hh), hepatitis delta virus ribozyme (δ), and T7
494 RNA polymerase terminator (T7t). (B) Growth kinetics of MV (blue) and MVny (red) in Vero cells
495 infected with an MOI of 0.1 (cell-associated virus titers are indicated in TCID₅₀/ml).

496
497 Figure 2: MVny induces NY-ESO-1 expression in human melanoma cell lines. (A) Western blot analysis
498 of NY-ESO-1 antigen expression in six human melanoma cell lines (M18, M45, M88, M117, M199 and
499 IPC 277/5). (B) Western blot analysis of NY-ESO-1 antigen expression in six melanoma lines (M18,
500 M45, M88, M117, M199, and IPC277/5) non-infected (NI) or infected by MV or MVny for 48 hours.

501
502 Figure 3: MVny induces the lysis of human melanoma cell lines. Melanoma cell lines were cultured
503 alone (NI) or with MV or MVny (MOI=1). After 48h (A-B) or 120h (C-D), cell death was measured by
504 annexin V and Propidium iodide (PI) staining and flow cytometry. (A and C) One representative
505 experiment with M88, M117 and M199 cell lines is shown. (B and D) Results (means + SD) of three
506 independent experiments performed with M18, M45, M88, M117, M199, and IPC277/5 cell lines are
507 shown. Percentages of dead cells are the sums of Annexin V+/PI-, Annexin V+/PI+ and Annexin V-
508 /PI+ cells.

509
510 Figure 4: MVny induces the recognition of melanoma cell lines by NY-ESO-1-specific CD4+ and CD8+
511 T cell clones. (A-C) The HLA-A*0201+ melanoma cell line M199 was cultured alone (NI), with MV or
512 MVny (MOI=1) during 48h (A) or 120h (B). Cells were collected and a part of M199 was pulsed with
513 the NY-ESO-1 (157-165) for one hour and washed. Cells were co-cultured with the CD8+ T cell clone
514 M117.167 for 5h in presence of brefeldin A and then fixed and stained for CD8 and intracellular IFN- γ .
515 Fluorescence was analyzed by flow cytometry. Results (means + SD) of three independent experiments

516 are shown (C). (D-F) The HLA-DPb1*0401+ melanoma cell line M88 was cultured alone (NI), with
517 MV or MVny (MOI=1) during 48h (D) or 120h (E). Cells were collected and a part of M88 was pulsed
518 with the NY-ESO-1 (157-170) for one hour and washed. Cells were co-cultured with the CD4+ T cell
519 clone NY67 for 5h in presence of brefeldin A, then fixed and stained for CD4 and intracellular IFN- γ .
520 Fluorescence was analyzed by flow cytometry. Results (means + SD) of three independent experiments
521 are shown (F).

522

523 Figure 5: MVny replicates in human monocyte-derived DC and induces NY-ESO-1 expression. (A)

524 Human monocyte-derived DC, the M88 melanoma cell line and N5.14 CD8+ T cell clones were exposed
525 to MVgfp (MOI=1) during 120h. The average fluorescence intensity is calculated from two different
526 locations in the same culture well per condition. (B) Microscopy picture of monocyte-derived DC 30h
527 after exposition to MVgfp. (C-D) Monocyte-derived DC and M88 melanoma cell line were exposed to
528 MV or MVny (MOI=1). (C) After 48h, cells were collected and *CTAG1B* expression was measured by
529 RT-qPCR and normalized to the expression of the housekeeping gene *RPLP0*. *CTAG1B* expression in
530 infected cells were compared to that of non-infected cells and results are expressed as log2 of fold
531 change. (D) After 48h, NY-ESO-1 and Actin were detected by western blot.

532

533 Figure 6: MVny induces the lysis of human monocyte-derived DC. Human monocyte-derived DC, the

534 M88 melanoma cell line and N5.14 CD8+ T cell clones were exposed to MV (MOI=1). (A-B) After
535 48h, 72h, 96h and 120h, cell death was measured by annexin V and propidium iodide (PI) staining and
536 flow cytometry. (B) Results (means + SD) of four independent experiments are shown. Percentages of
537 dead cells are the sums of Annexin V+/PI-, Annexin V+/PI+ and Annexin V-/PI+ cells and was retracted
538 from 100 to obtain % viability.

539

540 Figure 7: MVny induces the maturation of human monocyte-derived DC. Monocyte-derived DC were

541 cultured alone or with LPS, MV or MVny (MOI=1) for 48h. (A) Surface expressions of CD80, CD83,
542 CD86, HLA class I and HLA-DP were measured by flow cytometry. (B) Results (means + SD) of the
543 relative mean of fluorescence intensity (RMFI) from four independent experiments. RMFI were


544 obtained by the ratio of the mean fluorescence of cells stained by the specific mAb by the mean
545 fluorescence of cells stained with the isotype control. RMFI were normalized to non-infected cells
546 RMFI.

547

548 Figure 8: MVny induces the recognition of HLA-A*0201+ and HLA-DPb1*0401+ DC by NY-ESO-1-
549 specific CD8+ and CD4+ T cell clones. (A) HLA-DPb1*0401+ monocytes-derived DC were cultured
550 alone (NI) or with MV or MVny (MOI=1) during 48h. Cells were collected and a part of DC were pulsed
551 with the NY-ESO-1 (157-170) for one hour and washed. Cells were co-cultured with the CD4+ T cell
552 clone NY67 for 5h in presence of brefeldin A, then fixed and stained for CD4 and intracellular IFN- γ .
553 Fluorescence was analyzed by flow cytometry. (B) HLA-A*0201+ monocytes-derived DC were
554 cultured alone (NI) or with MV or MVny (MOI=1) during 48h. Cells were collected and a part of DC
555 were pulsed with the NY-ESO-1 (157-165) for one hour and washed. Cells were co-cultured with the
556 CD8+ T cell clone M17.167 for 5h in presence of brefeldin A, then fixed and stained for CD8 and
557 intracellular IFN- γ . Fluorescence was analyzed by flow cytometry. (C) Results (means + SD) of the
558 percentage of CD4+/IFN- γ + or CD8+/IFN- γ + cells of four independent experiments are shown.
559 Significance was determined in comparison of the NI DC condition.

Figure 1

A



B




Figure 2




Figure 3







Figure 4






Figure 5


A



B



C



D




Figure 6




Figure 7






Figure 8






A**B****C**

Figure S1: MVny does not modify recognition of the autologous HLA-A*0201+melanoma cell lines M117 by a NY-ESO-1 specific CD8+ T cell clone. The HLA-A*0201+melanoma cell lines M117 was cultured alone (NI) or with MV or MVny (MOI=1) during 48h or 120h. (A) Cells were collected and a part of M117 was pulsed with the peptide NY-ESO-1 (157-165) for one hour and washed. Cells were co-cultured with the CD8+ T cell clone M117.167 for 5h in presence of brefeldin A and then fixed stained for CD8 and IFN-g. (B) Results represents the mean with SD of three independent experiments. (C) NY-ESO-1 expression was measured in M18, M88 and M117 cell lines by RT-qPCR using RPLPO as a reference gene. M18 and M117 CTAG1B expression are expressed as log2 of fold change compared to M88 CTAG1B expression.




Figure S2: *MVny* does not induce the recognition of melanoma cell lines by a MUC1(950-956) specific CD8⁺ T cell clones and the NY-ESO-1 specific T cell clone does not recognize MV encoding cherry protein (MVch) infected tumor cell line. The HLA-A*0201⁺ melanoma cell line M199 was cultured alone (NI), with MV, MVch or MVny (MOI=1) during 48h. Cells were collected and a part of M199 was pulsed with the NY-ESO-1 (157-165) or MUC1(950-959) peptide for one hour and washed. Cells were co-cultured with the CD8⁺ T cell clone M117.167 or N5.14 for 5h in presence of brefeldin A and then fixed and stained for CD8 and intracellular IFN-g. N5.14 clone is specific of HLA-A*0201/MUC1(950-959) complex. Fluorescence was analyzed by flow cytometry.





Figure S3: MVny does not modify HLA-DP and HLA-A*0201 expression by M88 and M199 cell lines respectively. M88 and M199 cell lines were cultured alone or with MV or MVny (MOI=1) for 48h. (A) Surface expressions of HLA-DP on M88 and HLA-A μ 0201 by M199 were measured by flow cytometry. RMFI is indicated on histograms. (B) Results (means + SD) of the relative mean of fluorescence intensity (RMFI) from four independent experiments. RMFI were obtained by the ratio of the mean fluorescence of cells stained by the specific mAb by the mean fluorescence of cells stained with the isotype control. RMFI were normalized to non-infected MFI. RMFI were normalized to non-infected cells RMFI.




Figure S4: Type I interferons induced IFN γ production by CD4 $^{+}$ and CD8 $^{+}$ T cell clones. (A) NY67, the NY-ESO-1-specific CD4 $^{+}$ T cell clone was treated or not (NT) with IFN- α 2a (1000IU/mL) and IFN- β 1 (1000IU/mL) combined or not with Ruxolitinib (2 μ M) during 5h. Cells were fixed permeabilized and stained with fluorescent conjugated anti-CD4 and anti-IFN γ specific monoclonal antibodies. Fluorescence was analysed by flow cytometry. (B) HLA-DP4 $^{+}$ DCs were uninfected (Ni), or infected with MV or MVny for 48h (MOI 1). A part of Ni DC were pulsed with 10 μ M of NY-ESO-1 peptide. NY67 was then cultured with these DCs for 5h in presence of Ruxolitinib (2 μ M), a JAK1/2 inhibitor that inhibits IFNAR signalling and brefeldin A. Cells were fixed, permeabilized and stained with fluorescent conjugated anti-CD4 and anti-IFN- γ specific monoclonal antibodies. Fluorescence was analysed by flow cytometry. (C) M117.167, the NY-ESO-1-specific CD8 $^{+}$ T cell clone was treated or not (NT) with IFN α 2a (1000IU/mL) and IFN β 1 (1000IU/mL) combined or not with Ruxolitinib (2 μ M) during 5h. Cells were fixed permeabilized and stained with fluorescent conjugated anti-CD8 and anti-IFN γ specific monoclonal antibodies. Fluorescence was analysed by flow cytometry. (D) HLA-A2 $^{+}$ DCs were uninfected (Ni), or infected with MV or MVny for 48h (MOI 1). A part of Ni DC were pulsed with 10 μ M of NY-ESO-1 peptide. M117.167 was then cultured with these DCs for 5h in presence of Ruxolitinib (2 μ M), a JAK1/2 inhibitor that inhibits IFNAR signalling and brefeldin A. Cells were fixed, permeabilized and stained with fluorescent conjugated anti-CD8 and anti-IFN- γ specific monoclonal antibodies. Fluorescence was analysed by flow cytometry.